Cobenfy is the first approved drug in about 50 years to treat schizophrenia with a novel approach.
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but it's expensive.
The Food and Drug Administration has approved Iterum Therapeutics' Orlynvah, the first drug of its kind, which is designed to treat certain UTIs resistant to other drugs.
On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel treatment for schizophrenia in decades.
Two large-scale phase III trials have found that Bayer's elinzanetant can safely and effectively reduce hot flashes, paving the road to FDA approval.
